ethyl 3-(3-(2-propyl-4-cyclohexylphenoxy)propoxy)mandelate | 314050-91-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 3-(3-(2-propyl-4-cyclohexylphenoxy)propoxy)mandelate
• 英文别名: ethyl 2-[3-[3-(4-cyclohexyl-2-propylphenoxy)propoxy]phenyl]-2-hydroxyacetate
• CAS: 314050-91-4
• 化学式: C₂₈H₃₈O₅
• 分子量: 454.607
• InChiKey: WDRHEXVFRHWZNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  33
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 3-(3-(2-propyl-4-cyclohexylphenoxy)propoxy)mandelate 在 氨 、 sodium methylate 作用下， 以 甲醇 为溶剂， 生成 5-[3-(3-(2-propyl-4-cyclohexylphenoxy)propoxy)phenyl]-2,4-oxazolidinedione
  参考文献：
  名称：

  Aryloxazolidinediones: identification of potent orally active PPAR dual α/γ agonists

  摘要：

  A series of novel aryloxazolidine-2,4-diones was synthesized. A structure-activity relationship study of these compounds led to the identification of potent, orally active PPAR dual alpha/gamma agonists. Based on the results of efficacy studies in the db/db mice model of type 2 diabetes and the desired pharmacokinetic parameters, compound 12 was selected for further profiling. (C) 2003 Published by Elsevier Ltd.

  DOI：

  10.1016/s0960-894x(03)00785-6
• 作为产物：
  描述：

  3-氰基苯酚 在 盐酸 、 18-冠醚-6 、 三甲基氰硅烷 、 二异丁基氢化铝 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 ethyl 3-(3-(2-propyl-4-cyclohexylphenoxy)propoxy)mandelate
  参考文献：
  名称：

  Aryloxazolidinediones: identification of potent orally active PPAR dual α/γ agonists

  摘要：

  A series of novel aryloxazolidine-2,4-diones was synthesized. A structure-activity relationship study of these compounds led to the identification of potent, orally active PPAR dual alpha/gamma agonists. Based on the results of efficacy studies in the db/db mice model of type 2 diabetes and the desired pharmacokinetic parameters, compound 12 was selected for further profiling. (C) 2003 Published by Elsevier Ltd.

  DOI：

  10.1016/s0960-894x(03)00785-6

文献信息

• Arylthiazolidinedione derivatives
  申请人：Merck & Co., Inc.

  公开号：US20020037911A1

  公开（公告）日：2002-03-28

  Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR &agr; and/or &ggr; mediated diseases, disorders and conditions.

  取代5-芳基-2,4-噻唑烷二酮和噁唑烷二酮是PPAR的有效激动剂，因此在治疗、控制或预防糖尿病、高血糖、高脂血症（包括高胆固醇血症和高甘油三酯血症）、动脉粥样硬化、肥胖、血管再狭窄和其他PPARα和/或γ介导的疾病、疾病和情况中非常有用。
• Arylthiazolidinedione and aryloxazolidinedione derivatives
  申请人：Merck & Co. Inc.

  公开号：US06380191B1

  公开（公告）日：2002-04-30

  Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR &agr; and/or &ggr; mediated diseases, disorders and conditions.

  5-芳基-2,4-噻唑烷二酮和噁唑烷二酮的替代物是PPAR的有效激动剂，因此在糖尿病、高血糖、高脂血症（包括高胆固醇血症和高甘油三酯血症）、动脉硬化、肥胖症、血管再狭窄和其他PPARα和/或γ介导的疾病、紊乱和病状的治疗、控制或预防中是有用的。
• US6380191B1
  申请人：——

  公开号：US6380191B1

  公开（公告）日：2002-04-30
• US6465497B2
  申请人：——

  公开号：US6465497B2

  公开（公告）日：2002-10-15